Krystal Biotech (KRYS) Net Margin (2023 - 2026)

Krystal Biotech's Net Margin history runs 4 years deep, the most recent figure standing at 48.07% for Q1 2026.

• In Q1 2026, Net Margin rose 755.0% year-over-year to 48.07%; the TTM figure through Mar 2026 stood at 53.94% (up 1675.0% YoY), while the FY2025 annual figure was 52.64%, up 2195.0% from the prior year.
• Net Margin came in at 48.07% for Q1 2026 at Krystal Biotech, roughly flat from 47.99% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 943.75% in Q3 2023 to a low of 2.06% in Q1 2024.
• A 4-year average of 120.79% and a median of 40.52% in 2025 frame the typical range for Net Margin.
• Across the five-year window, Net Margin tumbled 91133 bps in 2024 and jumped 4873 bps in 2025, its largest moves.
• Krystal Biotech's Net Margin stood at 20.63% in 2023, then soared by 142 bps to 49.95% in 2024, then retreated by 4 bps to 47.99% in 2025, then gained by 0 bps to 48.07% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 48.07%, 47.99%, and 81.15% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison